| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
Human prion protein-expressing mice (KiChM mice) were intracerebrally inoculated with brain homogenate derived from sporadic Creutzfeldt-Jakob disease. At first, we compared the timing of administration of immortalized human messenchymal stromal cells (hMSC). The mice were divided into three groups (PBS, before onset-treatment and after onset-treatment group). When we compared survival periods, there were no significant differences between each group whereas after onset-treatment group survived 15 days longer than PBS group.
Next, we compared the number of cells for the administration between million cells and two million cells. The mice administered with million cells showed a significant prolongation of survival compared to the control group whereas the two million cells group did not. These results suggested that million hMSC is enough for the treatment of diseased mice.
|
